Atara Biotherapeutics, Inc. (ATRA) is a Healthcare stock trading at $10.05 (as of 2026-06-18), with a market capitalization of $86.77M and a trailing P/E of -8.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Atara Biotherapeutics, Inc. develops off-the-shelf T-cell immunotherapies for patients with cancer, autoimmune, and viral diseases in the United States. Its clinical-stage programs include tabelecleucel for EBV-driven post-transplant lymphoproliferative disease and tumors, as well as next-generation CAR T therapies targeting mesothelin, B-cell malignancies, and additional indications such as multiple sclerosis and HPV-associated cancers.